Machinery makers from Germany, Italy, Spain, China and the USA, and exhibitors from 23 countries in 2025: how Pharma Asia connects local plants to…
Official figures show a hard year for production and exports — and an ambitious roadmap to $10 billion in exports built on value addition.
DRAP has made PIC/S GMP its inspection reference and is phasing in the chapters. Pakistan is not yet a PIC/S member. Here is where things stand.
A May 2026 summit set a goal of local manufacture of at least 30% of medical devices by 2030, with a proposed Rs1 billion R&D fund.
Printing tablets layer by layer lets designers control how a drug is released. A look at the technology and how far it has come.
New excipients can enable abuse-deterrent and better-absorbed medicines. Why regulators created a special review route, and what it means for…
Two ways to take part, what each includes and which suits which company — from a first stand to a machinery display.
WHO estimates at least 1 in 10 medicines in low- and middle-income countries is substandard or falsified. Barcodes, GMP and dialogue are the response.
Five multinationals divested local manufacturing over three years, while national companies now hold nearly 80% of the market.
China is the largest international presence in the 2026 exhibitor list. Why that matters for an industry that imports most of its raw materials.
At the 23rd edition, the Governor and Chief Minister of Sindh set out why the pharmaceutical industry — and a platform for it — matters to the…
Pakistan makes most of its finished medicines but imports nearly all its active ingredients, mostly from China. The case for localisation, and what…
